Our latest insights
What We're Thinking
Mix Talent was engaged by an oncology focused-biotechnology company to fill R&D and Tech Ops positions.
In the life sciences, outsourcing talent is common practice. Over 15% of field team deployments in the healthcare commercial vertical are now made up of contract talent, 40% of clinical trial activities are outsourced through CROs, and more and more internal clinical roles within pharma companies are being filled with contract staff.
The workplace can be a challenging and unpredictable environment. Whether you’re working in the pharmaceutical industry, where healthcare providers are experiencing burnout like never before, or dealing with personal hardships like economic recessions or family illnesses, we all want to overcome the obstacles life throws our way.
Mix Talent was engaged by a major multinational pharmaceutical company to lead a neurological sales build for its US commercial subsidiary.
In response to a competitive, challenging life sciences market and customer demand, Mix is launching a new solution: Mix CTO (Contract Talent Organization). Mix CTO will provide life sciences organizations with rapid access to top talent spanning pre-commercial, medical affairs and sales organizations along with contingent talent augmentation for growing companies.
Throughout these past couple of years, we have witnessed a watershed moment for talent—for work in general. How, when, where, and why work gets done has been completely upended as we grapple with how to manage hybrid and remote workforces, how to keep good employees from jumping ship, and how to win the war for top talent without overspending on headcount.
Mix Talent is recognizing Rare Disease Day 2024 by celebrating rare heroes from across the country whose initiative, advocacy, and perseverance are making a difference in the lives of others.
After the positive reception to our inaugural Trends Report, we’re excited to introduce our 2024 Trends Report. Beyond reporting on what we learned, we have also added commentary throughout based on what we have seen transpire in life sciences talent this past year and how we expect it to evolve in the year to come.
In part 2 of our Special Edition Series - Cell and Gene Tx Journey to Commercialization - Abbey Jenkins (CEO, Gamida Cell) and Izzy Tyszler (VP of Commercial, Zevra Therapeutics) join ADVI Health’s Director of Health Policy and Reimbursement, Alicia Silver, to discuss commercialization of gene and cell therapies. Abbey and Izzy share their key learnings from past experiences leading commercial teams, including advice on how best to prepare for commercialization.
Periods of organizational or personal change demand executives and other corporate leaders to guide themselves and their teams through unpredictable challenges. During these times of instability, transitional coaching gives leaders the tools and clarity to navigate confidently through the turbulence.
Welcome back to The Mix Tape! In this 2-part special edition, Mix Talent teamed up with ADVI Health to bring together women leaders in Cell and Gene Therapy to discuss the journey from manufacturing to commercialization. This series will feature insights from our incredible guests on their learnings from past experiences, tips and tricks, and anticipated trends in biotech.
Mix Talent President Mickey Shimp shares the simple-but-effective advice his dad, Paul Shimp, gave him about being successful – and how that advice is put into action by the Mix O/S.